278 related articles for article (PubMed ID: 31226783)
21. Spleen tyrosine kinase inhibition: a new promising approach to chronic and refractory immune thrombocytopenia.
Niscola P; Scaramucci L; Giovannini M
Immunotherapy; 2018 Jan; 10(1):5-7. PubMed ID: 29192558
[No Abstract] [Full Text] [Related]
22. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Bajpai M
IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
Katsube T; Shimizu R; Fukuhara T; Kano T; Wajima T
Clin Pharmacokinet; 2019 Nov; 58(11):1469-1482. PubMed ID: 31055790
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure.
Terrault NA; Hassanein T; Howell CD; Joshi S; Lake J; Sher L; Vargas H; McIntosh J; Tang S; Jenkins TM
J Hepatol; 2014 Dec; 61(6):1253-9. PubMed ID: 25048952
[TBL] [Abstract][Full Text] [Related]
25. The Thrombopoietin Receptor Agonist Lusutrombopag Is Effective for Patients with Chronic Liver Disease and Impaired Renal Function.
Takeuchi H; Furuichi Y; Yoshimasu Y; Kasai Y; Abe M; Sugimoto K; Itoi T
J Nippon Med Sch; 2021 Jan; 87(6):325-333. PubMed ID: 32238734
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.
Cooper N; Ghanima W; Hill QA; Nicolson PL; Markovtsov V; Kessler C
Platelets; 2023 Dec; 34(1):2131751. PubMed ID: 36331249
[TBL] [Abstract][Full Text] [Related]
27. First Drug Approved to Reduce Bleeding Risk During Medical Procedures in Patients with Chronic Liver Disease.
Aschenbrenner DS
Am J Nurs; 2018 Sep; 118(9):22. PubMed ID: 30138198
[No Abstract] [Full Text] [Related]
28. Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment.
Sato S; Miyake T; Kataoka M; Isoda K; Yazaki T; Tobita H; Ishimura N; Kinoshita Y
Intern Med; 2017 Nov; 56(21):2887-2890. PubMed ID: 28943563
[TBL] [Abstract][Full Text] [Related]
29. Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease.
Al-Samkari H
Drugs Today (Barc); 2018 Nov; 54(11):647-655. PubMed ID: 30539164
[TBL] [Abstract][Full Text] [Related]
30. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.
Maan R; de Knegt RJ; Veldt BJ
Drugs; 2015 Nov; 75(17):1981-92. PubMed ID: 26501978
[TBL] [Abstract][Full Text] [Related]
31. New Drugs 2019, part 4.
Hussar DA
Nursing; 2019 Nov; 49(11):34-43. PubMed ID: 31651773
[TBL] [Abstract][Full Text] [Related]
32. Relationship between response to lusutrombopag and splenic volume.
Uojima H; Arase Y; Itokawa N; Atsukawa M; Satoh T; Miyazaki K; Hidaka H; Sung JH; Kako M; Tsuruya K; Kagawa T; Iwakiri K; Horie R; Koizumi W
World J Gastroenterol; 2018 Dec; 24(46):5271-5279. PubMed ID: 30581275
[TBL] [Abstract][Full Text] [Related]
33. Avatrombopag Effectively Maintained Platelet Counts in a Patient with Immune Thrombocytopenia Who Was Intolerant to Tyrosine Kinase Inhibitor Therapy.
Maitland HS
Am J Case Rep; 2021 Dec; 22():e933788. PubMed ID: 34862358
[TBL] [Abstract][Full Text] [Related]
34. Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients.
Dierickx D; Neefs J
Expert Opin Pharmacother; 2022 Jun; 23(8):885-892. PubMed ID: 35621338
[TBL] [Abstract][Full Text] [Related]
35. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies.
Kuter DJ; Allen LF
Br J Haematol; 2018 Nov; 183(3):466-478. PubMed ID: 30203841
[TBL] [Abstract][Full Text] [Related]
36. Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl.
Yoshida H; Yamada H; Nogami W; Dohi K; Kurino-Yamada T; Sugiyama K; Takahashi K; Gahara Y; Kitaura M; Hasegawa M; Oshima I; Kuwabara K
Exp Hematol; 2018 Mar; 59():30-39.e2. PubMed ID: 29274361
[TBL] [Abstract][Full Text] [Related]
37. Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient.
Sakamaki A; Watanabe T; Abe S; Kamimura K; Tsuchiya A; Takamura M; Kawai H; Yamagiwa S; Terai S
Clin J Gastroenterol; 2017 Jun; 10(3):261-264. PubMed ID: 28324272
[TBL] [Abstract][Full Text] [Related]
38. Fostamatinib (Tavalisse) for ITP.
Med Lett Drugs Ther; 2019 Feb; 61(1566):28-30. PubMed ID: 30845102
[No Abstract] [Full Text] [Related]
39. Managing periprocedural thrombocytopenia in cirrhosis: aiming for a safety window.
Bissonnette J; Valla D; Rautou PE
J Hepatol; 2014 Dec; 61(6):1199-201. PubMed ID: 25219886
[No Abstract] [Full Text] [Related]
40. Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension.
Al-Samkari H; Nagalla S
Platelets; 2022 Feb; 33(2):257-264. PubMed ID: 33586606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]